Day: November 7, 2025

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (NASDAQ: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Jefferies Global Healthcare Conference in London, November 17–20, 2025. Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Monday, November 17 from 7:30 – 7:55 AM ET (12:30 – 1 PM GMT), and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replays of the webcast will be available in the investor section of the Company’s website at https://ir.bioagelabs.com/, and...

WEST HARTFORD, Conn., Nov. 07, 2025 (GLOBE NEWSWIRE) — Legrand®, a global leader in electrical and digital building infrastructures, announced that it has acquired Avtron Power Solutions, a leading global provider of load banks and power quality solutions that serve a wide range of high-growth markets where reliable delivery of power is required. Avtron employs 600 people, operates five sites across North America and Europe, and is expected to generate nearly $350 million in revenue in 2025. With a commitment to innovation and quality, Avtron delivers dependable solutions for datacenters, healthcare facilities, renewable energy applications and industrial manufacturing sites to ensure that critical power is available when it’s needed by customers worldwide. Avtron will operate as a stand-alone business unit within Legrand’s Electrical...

CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor conference call and webcast on Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time (prior to market open). During the call, members of the NTHI management team and independent members of the company’s Scientific Advisory Board (SAB) will present data updates from the Company’s ongoing Phase 1/2a NEO100-1 clinical trial and compassionate use program, evaluating intranasal delivery of NEO100 (high-purity perillyl alcohol) in patients with recurrent high grade malignant...

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114 administration resulted in selective depletion of CCR8+ Tregs and a >50% increase in intratumoral CD8 T cells – turning tumors “hot” REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (NASDAQ: CHRS), today announced new multiomic tumor and blood-based biomarker data from the dose expansion arm of its ongoing Phase 1b clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic HNSCC. These data are being presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November...

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy, and in combination with anti-PD-1 antibody, was manageable and consistent with conditional binding of the AXL target restricted to the tumor microenvironment SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced clinical data in a poster titled “Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma...

GARDNER, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a product development order to build sub-assemblies that will support an advanced augmented reality (AR) system for US Air Force fighter pilot training, powered by POC’s next-generation optical sub-assembly design and manufacturing technologies. The program aims to allow pilots to wear AR headsets while in the air in their fighter jets, simulating combat training, without the need for secondary aircraft to be present. This reduces cost and the potential for training related accidents. The customer has been contracted by the US Air Force to deploy their solution on multiple aircraft platforms. This...

Partnership built to scale growing policy market and public demand to address future-state concerns around humanoid and robotic systems, recognizing ethical and operational demands and risks to help ensure non-lethal innovation MIAMI, Nov. 07, 2025 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (NASDAQ: WRAP), a global leader in non-lethal response and public-safety technology solutions, today announced the expansion of its partnership with the Law Enforcement Training and Advisory Council (“LETAC”) to address public concerns following the recent launch of consumer and public safety targeted humanoid robotic systems. Wrap is proactively developing human centered non-lethal response and policy frameworks with the aim to protect the public as future autonomous systems rapidly evolve. With a blueprint and program designed to maintain...

Saskatoon, SK, Nov. 07, 2025 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A), an award-winning, industry-leading developer of drone solutions and systems, announced today that it will host a shareholder update call on November 12, 2025, at 5:30 PM EST. The call will be led by Cameron Chell, Draganfly’s Chief Executive Officer, who will provide updates on the Company’s key milestones and strategic initiatives for the quarter. Paul Sun, Chief Financial Officer, will present highlights of the Company’s third quarter performance. Draganfly’s Q3 2025 financial results are scheduled for formal release after market close on November 12, 2025. Shareholders are invited to register for the call here: here. Pre-submitted investor questions are welcome and will be addressed during the call. Questions...